Equity Investment Corp GA Decreases Position in Johnson & Johnson (JNJ)
Equity Investment Corp GA decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 945,771 shares of the company’s stock after selling 71,094 shares during the period. Johnson & Johnson accounts for approximately 3.6% of Equity Investment Corp GA’s portfolio, making the stock its 10th largest position. Equity Investment Corp GA’s holdings in Johnson & Johnson were worth $114,722,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Americafirst Capital Management LLC purchased a new position in Johnson & Johnson during the second quarter worth approximately $101,000. INR Advisory Services LLC purchased a new position in Johnson & Johnson during the second quarter worth approximately $150,000. Capital Asset Advisory Services LLC purchased a new position in Johnson & Johnson during the second quarter worth approximately $202,000. NewSquare Capital LLC increased its position in Johnson & Johnson by 4.9% in the second quarter. NewSquare Capital LLC now owns 1,791 shares of the company’s stock worth $217,000 after buying an additional 83 shares during the period. Finally, Shayne & CO. LLC purchased a new position in Johnson & Johnson during the second quarter worth approximately $219,000. Institutional investors own 65.32% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) traded up 0.35% on Friday, hitting $119.16. 2,570,435 shares of the company were exchanged. Johnson & Johnson has a 52 week low of $94.12 and a 52 week high of $126.07. The company has a market capitalization of $326.01 billion, a price-to-earnings ratio of 22.21 and a beta of 0.62. The stock has a 50 day moving average of $118.90 and a 200 day moving average of $116.99.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.06. The business had revenue of $18.50 billion for the quarter, compared to the consensus estimate of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. Analysts predict that Johnson & Johnson will post $6.69 EPS for the current fiscal year.
A number of research firms recently commented on JNJ. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $123.14 price target for the company in a research note on Monday. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, September 28th. Credit Suisse Group AG reiterated a “neutral” rating and issued a $123.00 price target on shares of Johnson & Johnson in a research note on Monday, September 19th. Jefferies Group decreased their price target on Johnson & Johnson from $119.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, September 13th. Finally, Leerink Swann reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $120.19.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the transaction, the chief accounting officer now directly owns 28,660 shares in the company, valued at $3,582,786.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now owns 157,819 shares in the company, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.